Growth inhibition of a MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations

Abstract

Supernatants from Con A-stimulated rat spleen cell cultures containing T cell growth factor inhibited growth of a transplantable 3-methylcholanthrene-induced sarcoma in syngeneic mice. The tumour-inhibitory effects were dependent on the concentration of T cell growth factor and repeated injections of the supernatants.

Tumour inhibitory effects of TCGF/IL-2/-containing preparations

“…Fibrosarcoma MCll was induced with MC and transplanted in B10 mice as described earlier [1,2]. In vitro-cultured cells were used in the 20th-35th passages.…”

“…Paetkau et al [20] have demonstrated that a single IP injection of TCGF can exert a significant tumour-inhibitory effect in DBA/2 mice inoculated with syngeneic mastocytoma P815 cells. In a preliminary communication we have reported that supernatant from Con A-stimulated rat spleen cell cultures containing Offprint requests to: J. Bubenfk Abbreviations: TCGF, T cell growth factor; IL-2, interleukin 2; Con A, concanavalin A; 3H-TDR, tritiated thymidine; PMA, 4-/3-phorbol-12-/3-myristate-13-c~-acetate; NK, natural killer cells; B10, C57BL10/ScSnPH mice; FPLC, fast protein liquid chromatography; BSA, bovine serum albumin; OVA, ovalbumin; SBI, trypsin inhibitor from soybean; Cyt C, cytochrome C; OD, optical density; PBS, phosphate-buffered saline; MC, 3-methylcholanthrene TCGF is capable of inhibiting growth of a transplantable MC-induced sarcoma in syngeneic mice [2]. In this report we demonstrate that a similar effect can also be obtained with TCGF-containing supernatant of PMA-stimulated routine lymphoma EL-4TF cell cultures and with partially purified TCGF of monoclonal origin.…”

NK cell-based cancer immunotherapy: from basic biology to clinical application

“…It is well-known that IL-2, a growth factor that induces proliferation and expansion of lymphocytes and plays key roles in immune responses, can activate NK cells and enhance NK cytotoxicity against malignant cells [67]. Many studies using animal models have demonstrated the effectiveness of IL-2 on NK cell activation and anti-tumor responses [68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Robinson and Morstyn [82] has also reported that NK cells from lung cancer patients that fail to kill tumor cells, can regain the cytotoxicity against targets after activation by IL-2.…”

Interleukin-2 gene therapy of surgical minimal residual tumour disease

“…In the present study, experiments were designed to assess whether gene therapy based on utilization of IL-2 gene-modified tumour vaccines could be used to prevent local recurrences at the site of tumour resection and to cure the minimal residual tumour disease after surgery (SMRTD) in an experimental murine sarcoma system. We previously found that both local administration of IL-2 (Bubeník et al, 1983(Bubeník et al, , 1985 and local therapy with IL-2 gene-modified tumour vaccines (Bubeník et al, 1989(Bubeník et al, /1990 can substantially inhibit or prevent growth of small sarcoma inocula in syngeneic mice, as well as growth of various other experimental and human neoplasms (for review, see Rosenberg, 1992;Bubeník, 1994;Roth and Cristiano, 1997). To address the problem of tumour size, both macroscopic and microscopic ''surgical residues'' of methylcholanthrene (MC)-induced murine sarcoma MC12 were used for gene therapy.…”